NEEDHAM, Mass.--Robert Hennessey, chairman, president, and CEO of Genome Therapeutics in Waltham, Mass., has been elected a director of Repligen here. Repligen develops combinatorial chemistry synthesis and high-throughput screening technologies for the accelerated discovery of new drugs capable of blocking certain protein-carbohydrate and protein-protein interactions, for application in cancer and inflammatory disorders. Hennessey joined Genome Therapeutics in 1993 and refocused the company on genomics. He is also a director of PenWest Pharmaceuticals and Virus Research Institute.
Hennessey Elected Director of Repligen
Dec 18, 1998